수막염균 백신 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of meningococcal vaccines Market

The global meningococcal vaccines market is experiencing consistent expansion, supported by the rising incidence of invasive meningococcal diseases, expanding immunization programs, and continuous innovation in vaccine technology. As per the 2025 report year, the market size stood at USD 10.61 billion in 2025, reflecting the strong demand for preventive vaccination against life-threatening infections caused by Neisseria meningitidis. The market is projected to reach USD 4.12 billion in 2026 and further expand to USD 9.24 billion by 2034, driven by increased awareness, government-backed immunization strategies, and broader vaccine coverage against multiple serogroups.

Meningococcal disease includes severe conditions such as meningitis and septicemia, which progress rapidly and can be fatal if untreated. Among the 12 known serogroups of N. meningitidis, six-A, B, C, W, X, and Y-are responsible for the majority of global epidemics. Due to high mortality and long-term complications such as brain damage, hearing loss, and limb amputation, vaccination remains the most effective preventive strategy, fueling sustained market demand.

Market Overview and Key Insights

In 2025, North America dominated the meningococcal vaccines market with a 13.36% share, supported by advanced healthcare systems, strong surveillance infrastructure, and established national immunization schedules. The region recorded a market size of USD 2.21 billion in 2025, driven by rising disease incidence and proactive vaccination policies. The U.S. plays a central role due to increased reported cases and continuous product approvals aimed at adolescents, young adults, and high-risk populations.

Asia Pacific represents the fastest-growing regional market, supported by rising disease awareness, WHO-backed vaccination programs, and the availability of cost-effective vaccines from regional manufacturers. Europe maintains a strong position due to successful national immunization programs and high vaccine coverage rates, particularly among pediatric populations.

Market Dynamics

Market Drivers

The increasing global incidence of bacterial meningitis is a primary growth driver. According to the World Health Organization, 1 in 6 individuals with bacterial meningitis die, and 1 in 5 survivors experience permanent disabilities. In the U.S. alone, 438 meningococcal disease cases were reported in 2023, the highest number in a decade. Such data underscores the urgent need for widespread vaccination, boosting global market demand.

Market Restraints

The high cost of meningococcal vaccines limits adoption, particularly in low- and middle-income countries. Conjugate and multivalent vaccines require complex manufacturing processes and strict cold-chain logistics, increasing overall costs. Private-sector vaccine prices exceeding USD 170-230 per dose may restrict access for uninsured populations.

Market Opportunities

Government initiatives aimed at eliminating meningitis present strong growth opportunities. Global programs such as "Defeating Meningitis by 2030" are expanding immunization coverage in high-burden regions. WHO-supported rollout of affordable multivalent vaccines is increasing access and supporting long-term disease reduction.

Market Challenges

Cold-chain dependency and inadequate storage infrastructure remain major challenges. Vaccine wastage due to refrigeration failures and power disruptions continues to impose financial burdens on public health systems, limiting efficient vaccine distribution in resource-constrained regions.

Market Trends

A key trend shaping the market is the development of pentavalent (MenABCWY) vaccines, offering protection against the five most prevalent disease-causing serogroups. These vaccines simplify immunization schedules, reduce logistical complexity, and improve coverage efficiency. Recent regulatory approvals for pentavalent vaccines are accelerating adoption across adolescent and adult vaccination programs.

Segmentation Analysis

By Technology

The recombinant/conjugate/subunit vaccines segment held the largest market share, supported by superior immunogenicity and long-lasting protection. Innovations such as fully liquid, single-vial conjugate vaccines are further strengthening this segment. Inactivated vaccines maintain relevance in outbreak-driven mass immunization campaigns.

By Type

The MenACWY vaccines segment dominated due to inclusion in routine adolescent immunization schedules. MenB vaccines maintain steady demand, while MenABCWY vaccines are expected to grow at a faster pace due to broader serogroup coverage and recent approvals.

By Age Group

The pediatric segment leads the market, driven by national childhood vaccination programs and expanded indications for infants. Adult vaccination demand is also increasing due to rising disease incidence among high-risk populations.

By Distribution Channel

Government suppliers account for the largest share, leveraging bulk procurement and public immunization initiatives. Hospital and retail pharmacies are expanding access in urban and semi-urban areas.

Competitive Landscape

The meningococcal vaccines market is consolidated, with major players including GSK plc, Sanofi, and Pfizer Inc. holding a substantial share due to diversified vaccine portfolios and continuous R&D investments. Other significant contributors include Serum Institute of India, Walvax Biotechnology, Bio Farma, and Hualan Biological Vaccine, supporting global supply through affordable and region-specific vaccine solutions.

Report Coverage

The 2025 meningococcal vaccines market report delivers a comprehensive analysis of market size and value for 2025, 2026, and 2034, covering disease epidemiology, market dynamics, technology trends, segmentation, regional outlook, competitive landscape, and key industry developments. The report emphasizes vaccination coverage, regulatory progress, pipeline advancements, and global initiatives shaping the future of meningococcal disease prevention.

Conclusion

The global meningococcal vaccines market demonstrates a strong and structured growth outlook, underpinned by the rising incidence of invasive meningococcal diseases, expanding immunization coverage, and continuous advancements in multivalent vaccine development. With the market valued at USD 10.61 billion in 2025, projected to reach USD 4.12 billion in 2026, and expected to grow further to USD 9.24 billion by 2034, the market reflects sustained demand for effective preventive solutions against life-threatening meningococcal infections. North America's leadership, accounting for 13.36% market share in 2025, highlights the role of robust healthcare systems, surveillance programs, and routine vaccination schedules, while Asia Pacific's rapid growth underscores increasing access to affordable vaccines and global health initiatives. Despite challenges such as high vaccine costs, cold-chain dependency, and logistical constraints, strong government support, WHO-led programs, and the emergence of pentavalent vaccines covering major serogroups are reinforcing market fundamentals. Overall, the meningococcal vaccines market is positioned for steady long-term expansion, driven by public health priorities, technological innovation, and global efforts to reduce meningitis-related mortality and long-term complications.

Segmentation By Technology

• Recombinant/Conjugate/Subunit
• Inactivated
• Others

By Type

• MenACWY Vaccines
• MenB Vaccines
• MenABCWY Vaccines
• Others

By Age Group

• Pediatric
• Adults

By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

By Geography

• North America (By Technology, Type, Age Group, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
• Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Regulatory Scenarios, By Key Countries/Regions
• 4.2. Vaccination Coverage- By Key Countries/ Regions
• 4.3. Government Immunization Programs for Meningitis, By Key Countries/ Regions
• 4.4. Technological Advancements in Meningococcal Vaccines Market
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Technology
  • 5.1.1. Recombinant/Conjugate/Subunit
  • 5.1.2. Inactivated
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Type
  • 5.2.1. MenACWY Vaccines
  • 5.2.2. MenB Vaccines
  • 5.2.3. MenABCWY Vaccines
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Pediatric
  • 5.3.2. Adults
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital & Retail Pharmacies
  • 5.4.2. Government Suppliers
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Technology
  • 6.1.1. Recombinant/Conjugate/Subunit
  • 6.1.2. Inactivated
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Type
  • 6.2.1. MenACWY Vaccines
  • 6.2.2. MenB Vaccines
  • 6.2.3. MenABCWY Vaccines
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Pediatric
  • 6.3.2. Adults
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital & Retail Pharmacies
  • 6.4.2. Government Suppliers
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Technology
  • 7.1.1. Recombinant/Conjugate/Subunit
  • 7.1.2. Inactivated
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Type
  • 7.2.1. MenACWY Vaccines
  • 7.2.2. MenB Vaccines
  • 7.2.3. MenABCWY Vaccines
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Pediatric
  • 7.3.2. Adults
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital & Retail Pharmacies
  • 7.4.2. Government Suppliers
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Technology
  • 8.1.1. Recombinant/Conjugate/Subunit
  • 8.1.2. Inactivated
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Type
  • 8.2.1. MenACWY Vaccines
  • 8.2.2. MenB Vaccines
  • 8.2.3. MenABCWY Vaccines
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Pediatric
  • 8.3.2. Adults
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital & Retail Pharmacies
  • 8.4.2. Government Suppliers
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Technology
  • 9.1.1. Recombinant/Conjugate/Subunit
  • 9.1.2. Inactivated
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Type
  • 9.2.1. MenACWY Vaccines
  • 9.2.2. MenB Vaccines
  • 9.2.3. MenABCWY Vaccines
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Pediatric
  • 9.3.2. Adults
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital & Retail Pharmacies
  • 9.4.2. Government Suppliers
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Technology
  • 10.1.1. Recombinant/Conjugate/Subunit
  • 10.1.2. Inactivated
  • 10.1.3. Others
• 10.2. Market Analysis, Insights and Forecast - By Type
  • 10.2.1. MenACWY Vaccines
  • 10.2.2. MenB Vaccines
  • 10.2.3. MenABCWY Vaccines
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Pediatric
  • 10.3.2. Adults
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital & Retail Pharmacies
  • 10.4.2. Government Suppliers
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. GSK plc
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Sanofi
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merck & Co., Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Serum Institute of India Pvt. Ltd.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Novartis AG
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Walvax Biotechnology Co., Ltd.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Hualan Biological Vaccine Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Bio Farma
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. BioNet-Asia.
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)